<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1718_S04_C04_p033_046</title>
		<link href="BCSC1718_S04_C04_p033_046-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1718_S04_C04_p033_046" lang="en-US">
		<div id="_idContainer004" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter </span>4</p>
			<p class="chapter-title">Special Procedures</p>
			<p class="video-list-mid ParaOverride-2"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or going to www.aao.org/bcscvideo_section04.</p>
			<p class="body-text--no-indent-">New technologies have contributed to improvements in the diagnosis of infectious agents, dystrophies, degenerations, and neoplasms, as well as to the classification of neoplasms, especially the non-&#173;Hodgkin lymphomas and sarcomas. Specifically, refinements in immunohistochemical, flow cytometric, molecular genetic, and cytogenetic techniques allow a more accurate diagnosis and more precise definition of biomarkers of value in risk stratification, prognosis, and targeted therapeutics.</p>
			<p class="body-text">The ophthalmic surgeon is responsible for appropriately obtaining and submitting tissue for evaluation and consulting with the ophthalmic pathologist. See <span class="xref-table">Table&#160;4-1</span> for a checklist of important considerations when submitting tissue for pathologic consultation.</p>
			<p class="h1 ParaOverride-3">Immunohistochemistry</p>
				<div id="Chapt4_Top1">
			<p class="body-text--no-indent-">A given cell can express specific antigens; pathologists take advantage of this property when making a diagnosis. In the immunohistochemical stains commonly used in ophthalmic pathology, a primary antibody binds to a specific antigen in or on a cell, and a secondary antibody linked to a chromogen then binds to the primary antibody (<span class="xref-figure">Fig&#160;4-1</span>). Depending on the chromogen selected for use, the color product of the chromogens generally used in ophthalmic pathology is brown (see Fig&#160;4-1C) or red (see Fig&#160;4-5B) <br />in tissue sections. Red chromogen is especially helpful in working with ocular pigmented tissues and melanomas, because it differs from the brown melanin pigment in the uveal tissue or tumor.</p>
			<p class="body-text">The precise cell or cells that display the specific antigen can be identified using these methods. Many antibodies are used routinely for diagnosis, treatment, and prognosis:</p>
			<ul>
				<li class="bullet-list-first">cytokeratins for diagnosis of lesions composed of epithelial cells (eg, adenoma, carcinoma)</li>
				<li class="bullet-list-mid">desmin, myoglobin, or actin for diagnosis of lesions with smooth muscle or skeletal muscle features (eg, leiomyoma, rhabdomyosarcoma)</li>
				<li class="bullet-list-mid">S-100 protein for diagnosis of lesions of neuroectodermal origin (eg, schwannoma, neurofibroma, melanoma)</li>
				<li class="bullet-list-mid">HMB-45 and Melan&#160;A for diagnosis of melanocytic lesions (eg, nevus, melanoma)</li>
				<li class="bullet-list-mid">chromogranin and synaptophysin for diagnosis of neuroendocrine lesions (eg, metastatic carcinoid [see <span class="xref-figure">Fig&#160;4-1C</span>], small cell carcinoma)</li>
				<li class="bullet-list-mid">leukocyte common antigen for diagnosis of lesions of hematopoietic origin (eg, leukemia, lymphoma)</li>
				<li class="bullet-list-mid">CD antigens for subtyping white blood cells</li>
				<li class="bullet-list-mid">BAP1 for prognosis of neoplasia (eg, uveal melanoma)</li>
				<li class="bullet-list-mid">Her2Neu (eg, receptor tyrosine-&#173;protein kinase erbB-2, also known as CD340 or proto-&#173;oncogene Neu) for prognosis and treatment of breast carcinoma</li>
				<li class="bullet-list-last ParaOverride-4">Estrogen receptors for prognosis and treatment of neoplasia (eg, breast carcinoma)</li>
			</ul>
			<p class="body-text">These antibodies vary in their specificity and sensitivity. The specificities and sensitivities of new antibodies are continually being evaluated. In addition, automated equipment and antigen retrieval techniques are currently used to increase sensitivity and decrease turnaround time.</p>
			</div>
			<p class="h1">Flow Cytometry, Molecular Pathology, and Diagnostic Electron Microscopy</p>
				<div id="Chapt4_Top2">
			<p class="h2-h1">Flow Cytometry</p>
			<p class="body-text--no-indent-">Pathologists use flow cytometry (Fig&#160;4-2) to analyze the physical and chemical properties of particles or cells moving in single file in a fluid stream (see <span class="xref-figure">Fig&#160;4-2A,&#160;</span><span class="xref-figure CharOverride-1">a</span>). The most common use of flow cytometry in clinical practice is for immunophenotyping hematopoietic proliferations. This procedure may be performed on vitreous, aqueous, or ocular adnexal tissue. One example of flow cytometry is leukocyte immunophenotyping. For this procedure, the cells need to be fresh (unfixed). Fluorochrome-&#173;labeled specific antibodies bind to the surface of lymphoid cells, and a suspension of labeled cells is sequentially illuminated by a light source (usually an argon laser) for approximately 10<span class="superscript _idGenCharOverride-1">–6</span>&#160;second (see <span class="xref-figure">Fig&#160;4-2A,&#160;</span><span class="xref-figure CharOverride-1">b</span>). As the excited fluorochrome returns to its resting energy level, a specific wavelength of light is emitted (see <span class="xref-figure">Fig&#160;4-2A,&#160;</span><span class="xref-figure CharOverride-1">c</span>), which is sorted by wavelength stream (see <span class="xref-figure">Fig&#160;4-2A,&#160;</span><span class="xref-figure CharOverride-1">d</span>) and received by a photodetector (see <span class="xref-figure">Fig&#160;4-2A,&#160;</span><span class="xref-figure CharOverride-1">e</span>). The flow cytometer then converts this signal to electronic impulses, which are analyzed by computer software. The results may be represented by a multicolored dot-plot histogram (see <span class="xref-figure">Fig&#160;4-2,&#160;B and&#160;C</span>).</p>
			<p class="body-text">Flow cytometry’s advantage is that it actually shows the percentages of particular cells in a specimen. In addition, multiple antibodies and cellular size can be analyzed. For example, CD4 (helper T&#160;cells), CD8 (suppressor T&#160;cells), both CD4<span class="superscript _idGenCharOverride-1">+</span> and CD8<span class="superscript _idGenCharOverride-1">+</span>, or either CD4<span class="superscript _idGenCharOverride-1">+</span> or CD8<span class="superscript _idGenCharOverride-1">+</span> may be displayed for a given lymphocytic infiltrate. Flow cytometry’s disadvantages are its failure to show the location and distribution of these cells in tissue and the possibility of sampling errors. Depending on the number of cells in the sample and on clinical information, the flow cytometrist chooses the panel of antibodies to be tested. Flow cytometric data should therefore be used as an adjunct to morphologic hematoxylin-&#173;eosin (H&amp;E) staining and immunohistochemistry interpretation.</p>
			<p class="h2 ParaOverride-5">Molecular Pathology</p>
			<p class="body-text--no-indent-">Molecular biology techniques are used increasingly in diagnostic ophthalmic pathology and extensively in experimental pathology (<span class="xref-table">Table&#160;4-2</span>). More recently, the use of these techniques has expanded to include disease prognostication and treatment determination. Molecular pathology is used to identify tumor-&#173;promoting or tumor-&#173;inhibiting genes, such as the retinoblastoma gene (eg, via comparative genomic hybridization [CGH], <span class="italic">polymerase chain reaction</span> [PCR], or array CGH), and viral DNA or RNA strands, such as those seen in herpesviruses and Epstein-&#173;Barr virus (eg, via PCR or in situ hybridization [ISH]). Molecular pathology techniques have made it possible not only to recognize the presence or absence of a strand of nucleic acid but also to localize specific DNA sequences within specific cells (eg, via fluorescence in situ hybridization [FISH] or ISH). Two major techniques have markedly advanced our knowledge of developmental biology and tumorigenesis: PCR (and its variations) and microarray (and its subtypes).</p>
			<p class="h3 ParaOverride-6">Polymerase chain reaction</p>
			<p class="body-text--no-indent-">A common molecular biology technique is the PCR method, which amplifies a single strand of nucleic acid across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence (<span class="xref-figure">Fig&#160;4-3</span>). This method relies on thermal cycles of repeated heating and cooling of the DNA sample for thermal denaturation (DNA melting) and enzymatic replication. The components required for selective and repeated amplification are <span class="italic">primers,</span> which are short DNA fragments that contain sequences complementary to the target region, DNA polymerase, and nucleotides. PCR’s selectivity is due to the use of primers that are complementary to the DNA region targeted for amplification.</p>
			<p class="body-text">PCR techniques have advanced considerably in recent years, and there are now approximately 20&#160;PCR variations (see Table&#160;4-2 for a few of these). The clinical relevance of detecting a PCR product depends on numerous variables, including the primers selected, the laboratory controls, and the demographic considerations. Thus, clinicians making a clinicopathologic diagnosis should use PCR mainly to derive supplementary information. See also Part&#160;III, Genetics, in BCSC Section&#160;2, <span class="italic">Fundamentals and Principles of Ophthalmology.</span></p>
			<p class="h3">Microarray</p>
			<p class="body-text--no-indent-">Scientists and clinicians use microarrays to survey the expression of thousands of genes in a single assay, the output of which is called a <span class="italic">gene expression profile.</span> Microarray technology can help these scientists and clinicians try to understand fundamental aspects of growth and development, to explore the molecular mechanisms underlying normal and dysfunctional biological processes, and to elucidate the genetic causes of many human diseases. Some of the different types of microarrays available are DNA microarrays, <br />microRNA microarrays (MMChips), protein microarrays, tissue microarrays (<span class="xref-figure">Fig&#160;4-4</span>), cellular (or transfection) microarrays, antibody microarrays, and carbohydrate (glycoarray) microarrays.</p>
			<p class="body-text">The basic process underlying all of the DNA microarray platforms is straightforward: a glass slide or chip is spotted or “arrayed” with oligonucleotides or DNA fragments (called <span class="italic">probes</span>) that represent specific gene-&#173;coding regions. Fluorescently or chemiluminescently labeled purified cDNA or cRNA (called <span class="italic">target</span>) is hybridized to the arrayed slide or chip. After the chip is washed, the raw data are obtained by laser scanning, entered into a database (some public, others mined), and analyzed by statistical methods.</p>
			<p class="body-text">An example of one of these microarray platforms is a low-&#173;density DNA microarray. Although DNA microarrays were initially developed to quantify the expression of a limited number of genes of clinical relevance, the technology has also been applied to tumor diagnosis and tumor-&#173;acquired drug resistance. Validating the results of microarray experiments is a critical step in the analysis of gene expression. Quantitative real-time PCR is the chosen method for validating gene-&#173;expression profiling.</p>
			<p class="h3 ParaOverride-7">Clinical use of PCR and microarray</p>
			<p class="body-text--no-indent-">Routine clinical use of PCR and microarray has been traditionally limited to the diagnosis of leukemias, lymphomas, soft-&#173;tissue neoplasms, and tumors with nondiagnostic histopathology results. These methodologies have also been increasingly implemented in the detection of infectious agents (eg, the herpesvirus family), in tumor prognostication (eg, uveal melanoma), and in detection of genetic alterations that are amenable to targeted therapies (eg, cutaneous melanoma and hematologic malignancies). Some current commercial microarray and PCR platforms can now be used to assign biopsy-&#173;sized tumor samples to 1 of 2&#160;distinct molecular classes, based on gene expression analysis that distinguishes low-grade tumors from high-grade tumors.</p>
			<p class="body-text">The selection of commercially available microarray and PCR kits is growing rapidly. The continued refinement and wider commercial availability of molecular genetic techniques is expected to lead to progressive integration of these modalities into clinical practice and the pathologic evaluation of biopsy specimens. See also Part&#160;III, Genetics, in BCSC Section&#160;2, <span class="italic">Fundamentals and Principles of Ophthalmology.</span></p>
			<p class="reference-first">Khong JJ, Moore S, Prabhakaran VC, Selva D. Genetic testing in orbital tumors. <span class="italic">Orbit.</span> 2009;<br />28(2–3):88–97.</p>
			<p class="reference-mid">Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems [epub ahead of print July 5, 2012]. <span class="italic">J Biomed Biotechnol.</span> doi: 10.1155/2012/251364.</p>
			<p class="reference-last ParaOverride-8">Vaziri K, Schwartz SG, Kishor K, Flynn HW Jr. Endophthalmitis: state of the art. <span class="italic">Clin Ophthalmol.</span> 2015;9:95–108.</p>
			<p class="h2 ParaOverride-5">Diagnostic Electron Microscopy</p>
			<p class="body-text--no-indent-">Diagnostic electron microscopy (DEM) is primarily used to indicate the cell of origin of a tumor of questionable differentiation, rather than to distinguish between benign and malignant processes. Although immunopathologic studies are less expensive and performed more rapidly than DEM, DEM complements immunopathologic studies in some cases. The surgeon should consult with the pathologist before surgery to determine whether DEM should play a role in the study of a particular tissue specimen.</p>
			</div>
			<p class="h1 ParaOverride-9">Special Techniques</p>
				<div id="Chapt4_Top3">
			<p class="h2-h1">Fine-Needle Aspiration Biopsy</p>
			<p class="body-text--no-indent-">Intraocular fine-needle aspiration biopsy (FNAB) may be useful in distinguishing between primary uveal tumors and metastases. In cases of suspected uveal melanoma, biopsy specimens can undergo genetic analysis to identify prognostic chromosomal abnormalities and gene expression profiling patterns. Intraocular FNAB has also been utilized in the diagnosis of primary intraocular lymphoma. The biopsy specimens can undergo flow cytometric analysis, immunocytologic analysis, cytokine analysis, or molecular biological analysis (using PCR on both fixed and nonfixed material). Special fixatives are used for cytology specimens. See also Chapters&#160;17 and&#160;20 in this volume.</p>
			<p class="body-text">The procedure is performed under direct visualization through a dilated pupil, transvitreally (Video&#160;4-1) or transclerally (Video&#160;4-2). Iris tumors may be accessible for FNAB during slit-lamp biomicroscopy. FNAB alone may reliably predict the prognosis of a uveal melanoma. Intraocular FNAB may also enable tumor cells to escape the eye; this possibility is a controversial topic. In general, properly performed, FNAB does not pose a significant risk for seeding a tumor; however, retinoblastoma is a notable exception. FNAB of a possible retinoblastoma lesion, if indicated, should be performed by an <span class="italic">ophthalmic oncologist</span> with experience in making the diagnosis and performing the procedure.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,/9j/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAlgAAAAEAAQCWAAAAAQAB/+4AJkFkb2JlAGQAAAAAAQMAEAMDBgkAAAAAAAAAAAAAAAAFAAJJRP/bAIQAAgICAgICAgICAgMCAgIDBAMDAwMEBQQEBAQEBQUFBQUFBQUFBQcICAgHBQkKCgoKCQwMDAwMDAwMDAwMDAwMDAEDAgIDAwMHBQUHDQsJCw0PDQ0NDQ8PDAwMDAwPDwwMDAwMDA8MDg4ODg4MERERERERERERERERERERERERERER/8IAEQgAPAA7AwERAAIRAQMRAf/EALsAAQEBAQEBAQAAAAAAAAAAAAcIBQYCBAkBAQAAAAAAAAAAAAAAAAAAAAAQAAIBAwQCAgMAAAAAAAAAAAUGBAIDBwETFRcUFgBgEicoEQAABQMDAgQEAwUJAAAAAAABAgMEBRITBhEUFQAWISIyBzFBIxdhMyRCQ0QlNVGB4WJjs0U2NxIBAAAAAAAAAAAAAAAAAAAAYBMBAAIBAwEIAwAAAAAAAAAAAQARIfAxQVFgYXGBkaHB0RCx4f/aAAwDAQACEAMQAAAAKytSdDih7MwNRtDI6U+kFxNOEE4ooEguEQ8hmW6S+XiTUaxNocldE3meW6H5PpT5PQJnXlRhCWIflyNp4MAaARL1IREQ0TlCsSVBhMI6g2jOEEmYrYKClD//2gAIAQIAAQUB+gf/2gAIAQMAAQUB+gf/2gAIAQEAAQUBLFqhdXJNS0rjA1riHZ1ySpSkuHloRjuNEFAA78Zuga/TA/NyGMkDuZFUa+AyUCuRxBwhUELZKt3AA82WVBK8tuauzuXUJTae1citHGFOhDzKjRJnoQZ2vTjdSqx2w9Ol1qSK6nzITb7oT3bERa0aCzTaW4OThBRerAJzEtQINGPC78eBzriOfyjj/G2Quan/AA6bW2hnAwBC+ZygmyW4jkYkmoQF50a79pkiT780xARGVz9hyz4BZnukcr1NNCrZGv1l/hFBIzIgdNNK0FaSloTixNTi0nIxLosDumX6sDdPlrw644jNJvzGy7qjCh69fFJGQcc6ONsmbgHauignlCPw2AHVG43dQeyPnpPjKHWe7+tPUAfQHO/z74H/2gAIAQICBj8BAf/aAAgBAwIGPwEB/9oACAEBAQY/AcSEcSksrXyuSmBfvxmJ5K3annrMhSkZvUki0pJF/Z/xKhjOTykBEw+b5G1kXplI14m2hWUrbVUVGWMs6UOi2KYUwRKcTD6tR01b5xF+7MmszbNpGIdzDFVyCS00+Vcg2Mq3liELbOg5SR1bpjQr5/IBTKFwGQkm47rGuEbRkad+Zyu5MzY2pEhzRi7hBRJVymBvrnvj4UhTWAMn2OFbR+S5cnHG5xeUVcHYIbkwKrSjSaVOkmBiiIF26RhHQfw6iJ3M8/fe5TiAbqLSkSydv48zdq6lVG5HDMUuPMobdrFAQcG0t62/KCfUpMExeRzN/MZxl7RU/LTaJGyEc9RK3TIkweokANFh+Xy62W4mdt93O2KeblP6Twu82uu81/O81Xr+VWnh1PHQ9v8AMoPHofKeIfbbM5VkVqtIq3yODMiIltJq3wMBtKRE5fERMGr9I+LRLDD8VlJlqOYSGQozThJJ+5EkkuZkuACo9NRqQly6RXylGvx6wx1jiUVP+0Sz9OT5NWxxsW343YO2wIHE6KdwxDqlNqUd0pQAXtBNiEfh/ttIYLjknkUFLRGUtG7mWSfJoMV0o46bGwmQzhRu4rVTA4nE9VWptR6bYYvkjPLs9k3bds5lsxFKJTLGwCoSDW+g+OdNykqouoS8c2imgp+NAgEjyzV7k2UNmrQkyRBNZBabjRdoqoA/OiCgsLDoyZW5za3EE0Sk+mqTRTHIKHzmIyGelmrqbj46emGKbF5IqKmnFlW6SZCpgzWpL5tK6v2aetz2hOb/AG3cNPfT3XuO5tqLlPr2vjufj+7/AB6iY/CJkXmLZJJOebnj1S5mU8udfQ6jdqVwasrMwt0ymSFIuoHEAULcDIMVybGcgyKNnwRx/EsiePkFGccsyKZiq9kSxS6aQFTVOmoYVk7ugGFTz1dQmP4XJtmbPEnbuRZyeWOmDtOhreK/RaR0ae8oU4lWN+pRNomImIIGoMEqOZymPOYHNwaLuIqOjsidHJFs0Nsi5ilGSahURVTOUw+YDpialQCH1KAR8lk2NwCDRZLOFoFqJ5OYO0A/6ZmwePt6kuNTE1shVDAKhhA4CUQDpxI5RKxJZjMyosgg5NNHiGazFUjlAXz6JTI4TUMg1KcSqOALcNQBQ8pAe5PJQZIP7TvlypyWH2I08md2cRB7uZo21VbE2Go1COoHD4gPW97udcfyXd9vhHtXadrZ7DTY1X9359PXT4+jp/h+NZJJe2s1lTheKaxMep/NEnJHAzCkvKpCqnoKgNjJIjUpq3UIHgUwkLlOLzEfkZsuZQuZSDOReRjSMgJcyaCyy6y0e2dHQcgPgIGVRETVam8TdOM8weIgY/bw0fjgoQEW1XcJvZVJA6ikgmZukVoKib0U0zJCcxqiEHQDDoXCxfx0Bm0ZizyaXmu65hgMCycrNVToumiCFtM+q5BEgalPTUI6gHUOlgLvGX2USThwmxM3olmsewZJEWSdpkco/oVkVFFVEkW5bZzgAGOACIlTwlOosEq/cHnsxpCPxly4CSUX3yz5tqqufQCtbSqVBFPSPkKPUUxxeZlc+9s1IjjJSBcPlJKJbtlbQBtCuXSxVDAQhtUjlKUPAAHxGniuKdb279uf+0S9PNf1T8312Nt/FaX9fpUW/N1JYxFQsW99xJZdyhmr+Vx+SI2ShGSZ3LcyyW4SN/DNSgavQ46CHgIB0290mGGZGjAwWwXczcAgpERR490UBVVRipBu8cKo2gG+Yq2hg8wCUB16kJgudRzyGl3cailAINFF5Z0iVJq9ThhBNfUEzD+pH6WqZTCqYbYD1NYdlvs0gwYy7ls5vRb8jRW+sgsdEWpViuBWMzIqKKixfp3P2S1gXrEm0w4k84jxlGTRdxMRLl1sVBXS1pI025kTOSmBM7E4ivSUB1C6TpqXjkH8JIijzLeOdERySVRaqFtIpHOKpHSDcyRDjZb6olIZFU1xI5up9u99uZQMdYPmmQSTvF1ySzfITPzLqxbl0zatl1TpqFBcwCQ4AWoatai9f+xYjue1LNfMMat/v/Tc3Wm6s+XcaUU/Toq8/XuFjEbhSRMlYRCTPuhSsrVOEWbtHLrdFBUDKKAocSp2yCOtOvlA3UzG+2Xue4hWiTMCFaPo549QnEm6Rwag1TeMVzJqiTwcgIJo1mCgKA8IKJfSQYpleSy7qdn0YJquR8DeDh1DoKgpIJGRIoc0cQNEBAlA0m+J+sQy5k2Q94/cWfSfiMVJuVI8vForgUFlCpKMESOWw20RKmIFUqMcoKAFfWP4fMYY4Qm8448z5WVeSBwk5BZ0dGPdpnaOjWLK4arAe2qJACkDDp1kWYK5CyhvcbFnjppJpSgKvY9uk5UNZZI0lXVFIwOCLAZERPWNKptKy9RTKZcy2T5BwiiTWMdASBYxSqBUQcu360eWOOq1KYxbJEzmOUtYCUBENdx9z1LvL8/rtIXTkbW3uU7TSijwt+nXzaVePWLkmJTOJh/mcjLVqtMvexyDYiM29YJETblRWDQCIh8w6xaJXy1aKmST+cwTPMp+VVMpGRSD4jVf1hUsvZ0sjcJocA0/BtknuNPqDlWGQB4ly4inZo4TNZFZRNjNtVCCczhspvU27j0gUbo6mppGQfvoNqtE4zjTybQy9xiiChkZMizYyCse+M5qfJUqKGRHVLUgFHw+TGazmQCLiU10azSrk8I8cuXRikUnZI+i478gU7dMajJGSIYFtR8mA8AvDOhKuuzxadjnAJspZNBRxIOU3TYidLYxAKsJ1wOqKihfEpa/KE1lUxjTbF5WJytg0BXMDvd+5lTsDKtUHR49KwkjaKAABTAQDB4dbHsn9D3P2resFudsbXe8pcp/O3X0918aPp9POzvvXwHJyVniuA2V7euNzt73npv1/Hx6xbnO6q7WebruXZf2hz3Kbb5/Gi3/AJqvl1kfO907bm8f2lvZ8XytiM23G6/Uq2du7c8LVdPmp6c/dXvftjvxCzzey467bf0WbHn4+nXWrz/l/j0j9n/ujueHa8x2zxlWt5xa5HfeG4+P5flpp0+fQ73n/tXy47rcbbhtdv8AVu0fWs77Wqnx3ev7roeyuS2ndeJUcRa4zlf5jsqLvn09e4+fop+fX/EbDtD/AFqe299/tbr+/X8Ov//aAAgBAgMBPxDsB//aAAgBAwMBPxDsB//aAAgBAQMBPxAEBEgh/oQC10pCiUlnQqiCQhUxbf8Arudm82VaMWLdlj4KQK8nybzIqK6jdYnV1TZh7i/hTDTYTTD513cQPwTghtNIml6iwDGCKzvJe3g4SByiKWFDlZjgjDiraXCr4r6AXGuzeQGYThH1WgeICcjBlptSZQcyLhc+vDdZSA6HsYQAjIO4mk0O47bu7Hpi79H0kr5qMHtHGzSZtgnAbDkGWR7XQBcYZJnWxefQHUSpYjAWoeCLlWtYkRaVwZuhBI9WRAHqrDVupu0VLZqiSX7tsXHXaqRcAhnzIFLjtl+TjAlQkX2g+n4o45pUl/6Ev4hof0JaEVg+0kgIpXCibB6TOTuwxaXL8Jh9QQYsbT1g9Snxnj0kvipCNuyFCjGjyM9WCjwycp7EVAABrR6MGDEAr3urILwWutW1ClI324DIrqDJCe0x6TDqgi9TDHZ4HRoed43Ps0aXkYhe8KvCihwZRMvJnrh7lsGI9426RxgNpqDAvye2gt9T9TpIyHKLpYJWASsw0EjI5LpHTHB4yVno1gWq4WtV2BeGkkzeV3dg30A8UAR5qhSUVlnK7pkZNq4ARewKZxou7gVv4DllIjwgzfVABtoWuhFkDb8hPRiYGVc2Wc5BNmKkp01oeK/c63+XMTXPlXp/nZnwqZ399t5PyT5ktIJH+/LrAtz3rzJJqV3/AI/edF1Q4uz5qdGftx3/2Q==" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-7"><span class="QR-code-number">Video 4-1 </span>Transvitreal fine-needle aspiration biopsy.</p>
			<p class="QR-code-source">Courtesy of Thomas Aaberg, Jr, MD.</p>
			<p class="QR-code-text-last ParaOverride-10">Access all Section&#160;4 videos at www.aao.org/bcscvideo_section04.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-11"><span class="QR-code-number">Video 4-2 </span>Transscleral fine-needle aspiration biopsy.</p>
			<p class="QR-code-source ParaOverride-12">Courtesy of Thomas Aaberg, Jr, MD.</p>
			<p class="body-text">The cells obtained through FNAB can be processed through cytospin of fluid or preparation of a cell block (<span class="xref-figure">Fig&#160;4-5</span>). A cell block allows the pathologist to employ special stains, immunohistochemistry, ISH, microarray, and gene expression profiling, if needed.</p>
			<p class="body-text">Some orbital surgeons have used FNAB when diagnosing orbital lesions, especially presumed metastases to the orbit and optic nerve tumors (Video&#160;4-3). However, FNAB of orbital masses may not adequately sample all representative areas of the tumor, because it is difficult to make several passes at different angles through an intraorbital tumor. Specific indications for when to perform intraocular or intraorbital FNAB are beyond the scope of this discussion, but some of these indications are discussed in Chapters&#160;16 and 20 in Part&#160;II of this book, Intraocular Tumors: Clinical Aspects. Ophthalmic FNAB should be performed only when an ophthalmic pathologist or cytologist experienced in preparing and interpreting the specimens is available.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-13"><span class="QR-code-number">Video 4-3 </span>Orbital fine-needle aspiration biopsy.</p>
			<p class="QR-code-source ParaOverride-14">Courtesy of Jasmine Francis, MD.</p>
			<p class="reference-single ParaOverride-8">Eide N, Walaas L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: a review. <span class="italic">Acta Ophthalmol.</span> 2009;87(6):588–601.</p>
			<p class="h2 ParaOverride-6">Frozen Section</p>
			<p class="body-text--no-indent-">Permanent sections (tissue that is processed through alcohols and xylenes after fixation, embedded in paraffin, and sectioned) are always preferred in ophthalmic pathology because of the inherent small size of the samples. If the lesion is too small, it could be lost during frozen sectioning. A frozen section (tissue that is snap-&#173;frozen and immediately sectioned in a cryostat) is indicated when the results of the study will affect management of the patient in the operating room. For example, the most frequent indication for a frozen section is to determine whether the resection margins are free of tumor, especially in eyelid carcinomas. When tissue is submitted for margin evaluation, appropriate orientation of the specimen, correlated with documentation (through drawings of the excision site, labeled margins, or margins of the excised tissue that are tagged with sutures or other markers) is crucial.</p>
			<p class="body-text">Two techniques can be used for assessing the margins in eyelid carcinomas (eg, basal cell carcinoma, squamous cell carcinoma, and sebaceous carcinoma): routine frozen sections (as discussed previously) and Mohs micrographic surgery (<span class="xref-figure">Fig&#160;4-6</span>). Mohs surgery preserves tissue while obtaining free margins. Eyelid lesions, especially those located in the canthal areas, require tissue conservation to maintain adequate cosmetic and functional results.</p>
			<p class="body-text">Other frequent indications for frozen sections are to determine whether the surgeon has obtained, through biopsy, enough representative material for diagnosis (especially of metastasis) and to submit fresh tissue for flow cytometry and molecular genetics (eg, cancers). Frozen sections are a time-&#173;intensive and costly process and should be used with discretion.</p>
			<p class="body-text">See the section on eyelid disorders in BCSC Section&#160;7, <span class="italic">Orbit, Eyelids, and Lacrimal System,</span> for more information.</p>
			<p class="reference-single ParaOverride-8">Chévez-Barrios P. Frozen section diagnosis and indications in ophthalmic pathology. <span class="italic">Arch </span><span class="italic">Pathol Lab Med.</span> 2005;129(12):1626–1634.</p>
		</div>
		</div>
		<div id="_idContainer005" class="Basic-Text-Frame">
			<table id="table001" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-1">
							<p class="table-title"><span class="table-number">Table 4-1</span> Checklist for Requesting an Ophthalmic Pathologic Consultation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table CellOverride-2">
							<p class="table-head">Routine Specimens <span class="CharOverride-2">(cornea, conjunctiva, eyelid lesions)</span></p>
							<p class="table-body-ol1">&#9;1.&#9;Fill out requisition form with</p>
							<p class="table-body-ol2">a.&#9;Sex and age of patient</p>
							<p class="table-body-ol2">b.&#9;Location of lesion (laterality and exact location)</p>
							<p class="table-body-ol2">c.&#9;Previous biopsies of the site and diagnosis</p>
							<p class="table-body-ol2">d.&#9;Pertinent clinical history</p>
							<p class="table-body-ol2">e.&#9;Clinical differential diagnosis</p>
							<p class="table-body-ol2">f.&#9;Ophthalmologist phone and fax numbers</p>
							<p class="table-body-ol1">&#9;2.&#9;Submit specimen in adequately sealed container with</p>
							<p class="table-body-ol2">a.&#9;Ample amount of 10% formalin (at least 5&#160;times the size of the biopsy specimen)</p>
							<p class="table-body-ol2">b.&#9;Label with patient’s name and location of biopsy</p>
							<p class="table-body-ol1">&#9;3.&#9;Draw/map the site of biopsy for orientation of margins (eyelid lesions for margins, en bloc resections of conjunctiva, sclera, and ciliary body/iris tumors).</p>
							<p class="table-head ParaOverride-15">Frozen Sections</p>
							<p class="table-body-ol1">&#9;1.&#9;If possible, initiate communication with ophthalmic pathologist before requesting the section.</p>
							<p class="table-body-ol1">&#9;2.&#9;Fill out frozen section requisition form, specifying the reason for submitting tissue, such as</p>
							<p class="table-body-ol2">a.&#9;Margins</p>
							<p class="table-body-ol2">b.&#9;Diagnosis</p>
							<p class="table-body-ol2">c.&#9;Adequacy of sampling</p>
							<p class="table-body-ol2">d.&#9;Obtaining tissue for molecular diagnosis (eg, retinoblastoma, rhabdomyosarcoma, metastatic neuroblastoma) or flow cytometry</p>
							<p class="table-body-ol1">&#9;3.&#9;Map/diagram the lesion, indicating margins and orientation.</p>
							<p class="table-body-ol1">&#9;4.&#9;Label the tissue (ink, sutures) to orient according to the diagram (for margins).</p>
							<p class="table-head ParaOverride-15">Fine-Needle Aspiration Biopsy and Cytology</p>
							<p class="table-body-ol1">&#9;1.&#9;Initiate communication with ophthalmic pathologist before the biopsy to discuss</p>
							<p class="table-body-ol2">a.&#9;Logistics of the biopsy</p>
							<p class="table-body-ol3 ParaOverride-16">&#9;i.&#9;Possible adequacy check during the biopsy (intraocular tumors)</p>
							<p class="table-body-ol3 ParaOverride-16">&#9;ii.&#9;Fixative to be used</p>
							<p class="table-body-ol3 ParaOverride-16">&#9;iii.&#9;Fresh tissue for possible molecular diagnosis</p>
							<p class="table-body-ol2">b.&#9;Specific cytology form to be filled out</p>
							<p class="table-head ParaOverride-15">Flow Cytometry</p>
							<p class="table-body-ol1">&#9;1. &#9;Fresh tissue is critical.</p>
							<p class="table-body-ol1">&#9;2.&#9;Initiate communication with ophthalmic pathologist before the biopsy to discuss</p>
							<p class="table-body-ol2">a.&#9;Recommendations on fresh tissue transport (no media versus nutrient media, such <br />as RPMI)</p>
							<p class="table-body-ol2">b.&#9;Size of the sample needed</p>
							<p class="table-body-ol2">c.&#9;Geographic proximity to the laboratory</p>
							<p class="table-head ParaOverride-15">Molecular Techniques and Electron Microscopy</p>
							<p class="table-body-ol1">&#9;1.&#9;Initiate communication with ophthalmic pathologist before the biopsy to discuss</p>
							<p class="table-body-ol2">a.&#9;Differential diagnosis</p>
							<p class="table-body-ol2">b.&#9;Fixative (fresh vs alcohol vs glutaraldehyde vs other)</p>
							<p class="table-body-ol2">c.&#9;Logistics of the biopsy</p>
							<p class="table-body-ol3 ParaOverride-17">&#9;i.&#9;Time and date (availability of specialized personnel)</p>
							<p class="table-body-ol3 ParaOverride-17">&#9;ii.&#9;Geographic proximity to laboratory</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer008">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-8937.png" alt="" />
				</div>
				<div id="_idContainer007" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-1</span> Immunohistochemistry.<span class="figure-caption-bold"> A,</span>&#160;Schematic representation of the general immunohistochemistry method. (1),&#160;The cellular antigen is recognized by the specific primary antibody, (2),&#160;A secondary antibody, (3),&#160;directed against the primary antibody, reacts with the enzymatic complex to create the chromogen, (4),&#160;The final product allows the visualization of the cell containing the antigen. <span class="figure-caption-bold">B&#160;and&#160;C,</span> A metastatic carcinoid to the orbit seen by hematoxylin-&#173;eosin (H&amp;E) staining <span class="figure-caption-bold">(B)</span> shows bland epithelial characteristics. In <span class="figure-caption-bold">C,</span> a chromogranin antibody highlights the neuroendocrine nature of the cells. <span class="figure-source-note">(Courtesy of Patricia Chévez-&#173;Barrios, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011">
				<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-8940.png" alt="" />
				</div>
				<div id="_idContainer010" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-2</span> Flow cytometry. <span class="figure-caption-bold">A,</span>&#160;Flow cytometry analyzes particles or cells moving in single file in a fluid stream&#160;<span class="figure-caption-italic">(a).</span> Fluorochrome-&#173;labeled specific antibodies bind to the surface of cells, and a suspension of labeled cells is sequentially illuminated by a laser&#160;<span class="figure-caption-italic">(b).</span> As the excited fluorochrome returns to its resting energy level, a specific wavelength of light is emitted&#160;<span class="figure-caption-italic">(c),</span> which is sorted by wavelength&#160;<span class="figure-caption-italic">(d)</span> and received by a photodetector&#160;<span class="figure-caption-italic">(e).</span> This signal is then converted to electronic impulses, which are in turn analyzed by computer software. <span class="figure-caption-bold">B&#160;and&#160;C,</span> Flow cytometry scatter graphs showing a clonal population of CD19<span class="superscript _idGenCharOverride-1">+</span> kappa-&#173;restricted lymphocytes. Note that most of the CD19<span class="superscript _idGenCharOverride-1">+</span> <span class="figure-caption-italic">(red in part&#160;</span><span class="figure-caption-italic CharOverride-3">B</span><span class="figure-caption-italic">)</span> cells fail to express lambda light chains; however, the cells do exhibit strong kappa expression <span class="figure-caption-italic">(red in part&#160;</span><span class="figure-caption-italic CharOverride-3">C</span><span class="figure-caption-italic">).</span> <span class="figure-source-note">(Courtesy of Patricia Chévez-&#173;Barrios, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer012" class="Basic-Text-Frame">
			<table id="table002" class="Basic-Table TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-4" />
					<col class="_idGenTableRowColumn-5" />
					<col class="_idGenTableRowColumn-6" />
					<col class="_idGenTableRowColumn-5" />
					<col class="_idGenTableRowColumn-7" />
					<col class="_idGenTableRowColumn-5" />
					<col class="_idGenTableRowColumn-8" />
				</colgroup>
				<thead>
					<tr class="Basic-Table _idGenTableRowColumn-2">
						<td class="Basic-Table CellOverride-3 _idGenCellOverride-1" colspan="7">
							<p class="table-title"><span class="table-number">Table 4-2</span> Summary of Molecular Techniques Used in Diagnostic Pathology</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-9">
						<td class="Basic-Table CellOverride-4">
							<p class="table-column-head">Technique</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-column-head">Method</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-column-head">Advantages</p>
						</td>
						<td class="Basic-Table CellOverride-4" />
						<td class="Basic-Table CellOverride-4">
							<p class="table-column-head">Disadvantages</p>
						</td>
					</tr>
				</thead>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-18">Comparative genomic hybridization (CGH)</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-18">Molecular cytogenetic method for analysis of copy number changes (gains/losses) in the DNA content of an individual, often in tumor cells. Uses epifluorescence and quantitative, regional differences in the fluorescence ratio of gains/losses vs control DNA to identify abnormal regions in <br />the genome at a resolution of 20–80 base pairs</p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-numbered-list">1.&#9;Detects and maps alterations in copy number of DNA sequences</p>
							<p class="table-numbered-list">2.&#9;Analyzes all chromosomes in a single experiment and does not require division <br />of cells </p>
						</td>
						<td class="Basic-Table CellOverride-5" />
						<td class="Basic-Table CellOverride-5">
							<p class="table-body ParaOverride-18">Inability to detect mosaicism, balanced chromosomal translocations, inversions, or whole-genome ploidy changes</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-18">Polymerase chain reaction (PCR) </p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-18">Amplification of a single strand of DNA (nucleic acid) based on thermal cycles of repeated heating and cooling of the sample for DNA melting and enzymatic replication of the DNA. Clinically used for early detection of cancer, hereditary diseases, and infectious diseases</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-body ParaOverride-18">Quality snap-frozen tissue (optimal) and archival paraffin-embedded tissue</p>
						</td>
						<td class="Basic-Table CellOverride-6" />
						<td class="Basic-Table CellOverride-6">
							<p class="table-numbered-list">1.&#9;Variable success rate of DNA extraction</p>
							<p class="table-numbered-list">2.&#9;Contamination with other nucleic acid material</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table CellOverride-7">
							<p class="table-body ParaOverride-18">Fluorescence in situ hybridization (FISH) </p>
						</td>
						<td class="Basic-Table CellOverride-7" />
						<td class="Basic-Table CellOverride-7">
							<p class="table-body ParaOverride-18">Chromosome region-specific, fluorescently labeled DNA probes (cloned pieces of genomic DNA) able to detect their complementary DNA sequences </p>
						</td>
						<td class="Basic-Table CellOverride-7" />
						<td class="Basic-Table CellOverride-7">
							<p class="table-body ParaOverride-18">Microfluidic chip allows automation and clinical use </p>
						</td>
						<td class="Basic-Table CellOverride-7" />
						<td class="Basic-Table CellOverride-7">
							<p class="table-body ParaOverride-18">Known type and location of expected aberrations</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-13">
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-18">Reverse transcriptase-polymerase chain reaction (RT-PCR) </p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-18">Amplifies DNA from RNA. Clinically used to determine the expression of a gene</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-body ParaOverride-18">Quality snap-frozen tissue (optimal) and archival paraffin-embedded tissue</p>
						</td>
						<td class="Basic-Table CellOverride-8" />
						<td class="Basic-Table CellOverride-8">
							<p class="table-numbered-list">1.&#9;Variable success rate of RNA extraction</p>
							<p class="table-numbered-list">2.&#9;Contamination with other nucleic acid material</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-14">
						<td class="Basic-Table CellOverride-9">
							<p class="table-body ParaOverride-18">Real-time quantitative PCR (RT-PCR)</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body ParaOverride-18">Measurement of PCR-product accumulation during the exponential phase of the PCR reaction using a dual-labeled fluorogenic probe</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body ParaOverride-18">Direct detection of PCR-product formation by measuring the increase in fluorescent emission continuously during the PCR reaction</p>
						</td>
						<td class="Basic-Table CellOverride-9" />
						<td class="Basic-Table CellOverride-9">
							<p class="table-body ParaOverride-18">Variable success rate of RNA extraction</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-15">
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Multiplex ligation-dependent probe amplification (MLPA)</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Amplification of multiple targets using only a single primer pair within a single PCR mixture to produce amplicons of varying sizes that are specific to different DNA sequences</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Additional information may be gained from a single test run.</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Targets must be different enough to form distinct bands when visualized by gel electrophoresis.</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-16">
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Next-generation sequencing (massively parallel sequencing) </p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-body ParaOverride-18">Parallelization of the sequencing process, producing thousands or millions of sequences concurrently. Used in genome sequencing and resequencing, transcriptome profiling (RNA-seq), DNA-protein interactions (ChIP-sequencing), and epigenome characterization. </p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-numbered-list">1.&#9;Ability to rapidly sequence the entire genome</p>
							<p class="table-numbered-list">2.&#9;Reduced reagent costs</p>
							<p class="table-numbered-list">3.&#9;Small amounts of starting material required</p>
							<p class="table-numbered-list">4.&#9;High precision with some methodologies</p>
						</td>
						<td class="Basic-Table CellOverride-10" />
						<td class="Basic-Table CellOverride-10">
							<p class="table-numbered-list">1.&#9;Short sequencing read lengths and higher error rates with some methodologies</p>
							<p class="table-numbered-list">2.&#9;Equipment can be expensive</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-17">
						<td class="Basic-Table CellOverride-11">
							<p class="table-body ParaOverride-18">SNP oligonucleotide microarray analysis (SOMA) </p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-body ParaOverride-18">Type of DNA microarray used to detect single nucleotide polymorphisms (SNPs), the most frequent type of variation in the genome, within a population. Uses an array containing immobilized nucleic acid sequences and <br />1 or more labeled allele-specific oligonucleotide probes</p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-numbered-list">1.&#9;SNPs, which are highly conserved between species and within a population, serve as a genotypic marker for research.</p>
							<p class="table-numbered-list">2.&#9;Able to detect copy-neutral loss of heterozygosity to uniparental disomy</p>
							<p class="table-numbered-list">3.&#9;Has huge potential in cancer diagnostics </p>
						</td>
						<td class="Basic-Table CellOverride-11" />
						<td class="Basic-Table CellOverride-11">
							<p class="table-body ParaOverride-18">Unable to detect mosaicism, balanced chromosomal translocations, inversions, or whole-genome ploidy changes</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer013" class="Basic-Text-Frame _idGenObjectStyleOverride-2">
			<p class="table-title"><span class="CharOverride-4">(continued)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer016">
				<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-7445.png" alt="" />
				</div>
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-3</span> Polymerase chain reaction (PCR). <span class="figure-caption-bold">A,</span>&#160;PCR starts with a denaturing step in which DNA samples are heated to 95°C to separate the target DNA into single strands. <span class="figure-caption-bold">B,</span>&#160;The temperature is then lowered to 55°C to allow the primers to anneal to their complementary sequences. The primers are designed to bracket the DNA region to be amplified. <span class="figure-caption-bold">C,</span>&#160;The temperature is raised to 72°C to allow Taq polymerase to attach at each priming site and extend or synthesize a new DNA strand between primer sequences, producing 2&#160;new DNA molecules. <span class="figure-caption-bold">D,</span>&#160;Step C is repeated multiple times to generate thousands to millions of copies. <span class="figure-source-note">(Courtesy of Theresa Kramer, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer019">
				<div id="_idContainer017" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-4291.png" alt="" />
				</div>
				<div id="_idContainer018" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-4</span> Tissue microarrays are constructed with small core biopsies of different tumors/<br />tissues. A core is obtained from the donor paraffin block of the tumor&#160;<span class="figure-caption-italic">(a).</span> A recipient paraffin block is prepared, creating empty cores&#160;<span class="figure-caption-italic">(b).</span> The cores are incorporated into the slots&#160;<span class="figure-caption-italic">(c)</span> until all are occupied&#160;<span class="figure-caption-italic">(d).</span> Glass slides are prepared and stained with a selected antibody&#160;<span class="figure-caption-italic">(e).</span> Microscopic examination reveals the different staining patterns of each core&#160;<span class="figure-caption-italic">(f).</span> <span class="figure-source-note">(Courtesy of Patricia Chévez-&#173;Barrios, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer022">
				<div id="_idContainer020" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-4293.png" alt="" />
				</div>
				<div id="_idContainer021" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-5</span> Fine-&#173;needle aspiration biopsy (FNAB) of choroidal tumor. <span class="figure-caption-bold">A,</span>&#160;Cytologic liquid-&#173;based preparation displays prominent nucleoli <span class="figure-caption-italic">(arrow)</span> and some brown pigment <span class="figure-caption-italic">(arrowhead)</span> suggestive of melanoma. <span class="figure-caption-bold">B,</span>&#160;Cell block of the aspirated cells, stained with HMB-45 using a red chromogen, is positive, confirming the diagnosis of melanoma. Notice the difference between the red chromogen <span class="figure-caption-italic">(arrows)</span> and the brown melanin <span class="figure-caption-italic">(arrowheads).</span> <span class="figure-source-note">(Courtesy of Patricia Chévez-&#173;Barrios, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer025">
				<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1718_S04_C04_p033_046-web-resources/image/AAX-8947.png" alt="" />
				</div>
				<div id="_idContainer024" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 4-6</span> Frozen section and Mohs micrographic surgery techniques. <span class="figure-caption-bold">A,</span>&#160;To prepare a frozen section, the surgeon excises lesions with a surgical margin. For an eyelid margin lesion, the surgeon performs a wedge eyelid resection. The pathologist samples the nasal&#160;(N), temporal&#160;(T), and inferior margins. A central cross &#173;section&#160;(C) demonstrates the distance of the tumor from the inferior surgical margin. Similarly, an elliptical excision of the tumor can be evaluated by the bread-loaf technique in which multiple cross sections&#160;(C) are prepared. <span class="figure-caption-bold">B,</span>&#160;In Mohs micrographic surgery performed on an eyelid margin tumor, the surgeon excises the visible lesion. Then, additional thin shavings of tissue are prepared from the bed of the residual defect, allowing the surgeon to evaluate en face margins (EF). In another variation of Mohs surgery, the surgeon performs an elliptical excision of the visible tumor. Frozen en face (EF) sections <br />are obtained from the undersurface and the edges of the excised lesion. The tumor locations are marked on a map for a subsequent second-&#173;stage excision. <span class="figure-source-note">(Illustration developed by Tatyana Milman, MD, a</span><span class="figure-source-note">nd rendered by Mark Miller.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
